Your browser doesn't support javascript.
loading
Rate of breast biopsy referrals in female BRCA mutation carriers aged 50 years or more: a retrospective comparative study and matched analysis.
Pomerantz, Adi; Tsoref, Daliah; Grubstein, Ahuva; Wadhawker, Sonya; Rapson, Yael; Gadiel, Itay; Goldvaser, Hadar; Feldhamer, Ilan; Hammerman, Ariel; Shochat, Tzipora; Sharon, Eran; Kedar, Inbal; Yerushalmi, Rinat.
Affiliation
  • Pomerantz A; Institute of Oncology, Davidoff Cancer Center, Rabin Medical Center, Beilinson Hospital, Petah Tikva, 4941492, Israel.
  • Tsoref D; Institute of Oncology, Davidoff Cancer Center, Rabin Medical Center, Beilinson Hospital, Petah Tikva, 4941492, Israel.
  • Grubstein A; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, 69978, Israel.
  • Wadhawker S; Imaging Department, Rabin Medical Center, Beilinson Hospital, Petah Tikva, 4941492, Israel.
  • Rapson Y; Surgery Department, Breast Cancer Unit, Rabin Medical Center, Beilinson Hospital, Petah Tikva, 4941492, Israel.
  • Gadiel I; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, 69978, Israel.
  • Goldvaser H; Imaging Department, Rabin Medical Center, Beilinson Hospital, Petah Tikva, 4941492, Israel.
  • Feldhamer I; Imaging Department, Rabin Medical Center, Beilinson Hospital, Petah Tikva, 4941492, Israel.
  • Hammerman A; Institute of Oncology, Davidoff Cancer Center, Rabin Medical Center, Beilinson Hospital, Petah Tikva, 4941492, Israel.
  • Shochat T; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, 69978, Israel.
  • Sharon E; Chief Physician's Office, Clalit Health Services Headquarters, Tel Aviv, 6340412, Israel.
  • Kedar I; Chief Physician's Office, Clalit Health Services Headquarters, Tel Aviv, 6340412, Israel.
  • Yerushalmi R; Statistical Consulting Unit, Rabin Medical Center, Beilinson Hospital, Petah Tikva, 4941492, Israel.
Breast Cancer Res Treat ; 193(2): 507-514, 2022 Jun.
Article in En | MEDLINE | ID: mdl-35391652
ABSTRACT

PURPOSE:

To evaluate the total biopsy and positive biopsy rates in women at high risk of breast cancer compared to the general population.

METHODS:

The study group consisted of 330 women with pathogenic variants (PVs) in BRCA1/2 attending the dedicated multidisciplinary breast cancer clinic of a tertiary medical center in Israel. Clinical, genetic, and biopsy data were retrieved from the central healthcare database and the medical files. Patients aged 50 years or older during follow-up were matched 110 to women in the general population referred for routine breast cancer screening at the same age, as recommended by international guidelines. The groups were compared for rate of biopsy studies performed and percentage of positive biopsy results. Matched analysis was performed to correct for confounders.

RESULTS:

The total biopsy rate per 1000 follow-up years was 61.7 in the study group and 22.7 in the control group (p < 0.001). The corresponding positive biopsy rates per 1000 follow-up years were 26.4 and 2.0 (p < 0.001), and the positive biopsy percentages, 42.9% and 8.7% (p < 0.0001).

CONCLUSION:

Women aged 50 + years with PVs in BRCA1/2 attending a dedicated clinic have a 2.7 times higher biopsy rate per 1000 follow-up years, a 13.2 times higher positive biopsy rate per 1000 follow-up years, and a 4.9 times higher positive biopsy percentage than same-aged women in the general population.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Breast Neoplasms Type of study: Diagnostic_studies / Guideline / Observational_studies / Risk_factors_studies Limits: Female / Humans / Middle aged Language: En Journal: Breast Cancer Res Treat Year: 2022 Document type: Article Affiliation country:

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Breast Neoplasms Type of study: Diagnostic_studies / Guideline / Observational_studies / Risk_factors_studies Limits: Female / Humans / Middle aged Language: En Journal: Breast Cancer Res Treat Year: 2022 Document type: Article Affiliation country:
...